Risk-adapted management for patients with clinical stage I seminoma: The second Spanish Germ Cell Cancer Cooperative Group study

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8717-8723

  Aparicio, Jorge ^a   Germà, José R ^b   Del Muro, Xavier García ^b   Maroto, Pablo ^b   Arranz, José A ^b   Sáenz, Alberto ^b   Barnadas, Agustín ^b   Dorca, Joan ^b   Gumà, Josep ^b   Olmos, David ^b   Bastús, Romá ^b   Carles, Joan ^b   Almenar, Daniel ^b   Sánchez, Miguel ^b   Paz Ares, Luis ^b   Satrústegui, Juan J ^b   Mellado, Begoña ^b   Balil, Ana ^b   López Brea, Marta ^b   Sánchez, Alfredo ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN BETA SUBUNIT;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MUCOSA INFLAMMATION; NEUROTOXICITY; ORCHIECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETE TESTIS; RETROPERITONEAL CANCER; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SEMINOMA; SIDE EFFECT; SPERMATIC CORD; THERAPY DELAY; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING; ADJUVANT CHEMOTHERAPY; ADOLESCENT; AGE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PATHOLOGY; PROSPECTIVE STUDY; TESTIS TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPENIA; ORCHIECTOMY; PROSPECTIVE STUDIES; RISK FACTORS; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 33644660123     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.9810     Document Type: Article

References (24)

1. Chang SS, Roth B: Treatment of clinical stage I germ cell tumors. Urology 59:173-179, 2002
2. Zagars GK: Management of stage I seminoma: Radiotherapy, in Horwich A (ed): Testicular Cancer: Investigation and Management (ed 2). London, United Kingdom, Chapman & Hall, 1996, pp 99-121
3. Warde P, Specht L, Norwich A, et al: Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 20:4448-4452, 2002
4. Sternberg CN: The management of stage I testis cancer. Urol Clin North Am 25:435-449, 1998
5. Oliver RT, Mason M, Von der Masse H, et al: A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE 19/EORTC 30982. Proc Am Soc Clin Oncol 23:385, 2004 (abstr 4517)
6. Aparicio J, García del Muro X, Maroto P, et al: Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14:867-872, 2003
7. Hermanek P, Sobin LH: UICC: TNM Classification of Malignant Tumours (ed 5). Berlin, Germany, Springer, 1997
8. Arranz JA, García del Muro X, Gumà J, et al: E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification: The Spanish Germ Cell Cancer Group experience. Ann Oncol 12:487-491, 2001
9. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
10. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
11. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
12. Germà-Lluch JR, García del Muro X, Maroto P, et al: Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: The experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 42:553-563, 2002
13. Zagars GK, Ballo MT, Lee AK, et al: Mortality after cure of testicular seminoma. J Clin Oncol 22:640-647, 2004
14. Fossa SD, Horwich A, Russell JM, et al: Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. J Clin Oncol 17:1146-1154, 1999
15. Jones WG, Fossa SD, Mead GM, et al: Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: A report on Medical Research Council trial TE18, European Organization for the Research and Treatment of Cancer trial 30942 (ISRCTN18525328). J Clin Oncol 23:1200-1208, 2005
16. Sharda NN, Kinsella TJ, Ritter MA: Adjuvant radiation versus observation: A cost analysis of alternate management schemes in early-stage testicular seminoma. J Clin Oncol 14:2933-2939, 1996
17. Fossa SD, Moynihan C, Serbouti S: Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I: A descriptive pilot study. Support Care Cancer 4:118-128, 1996
18. Oliver RTD, Edmonds PM, Ong YJH, et al: Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: Should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 29:3-8, 1994
19. Dieckmann KP, Brüggeboes B, Pichlmeier U, et al: Adjuvant treatment of clinical stage I seminoma: Is a single course of carboplatin sufficient? Urology 55:102-106, 2000
20. Reiter WJ, Brodowicz T, Alavi S, et al: Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19:101-104, 2001
21. Steiner H, Höltl L, Wirtenberger W, et al: Long-term experience with carboplatin monotherapy for clinical stage I seminoma: A retrospective single-center study. Urology 60:324-328, 2002
22. Cullen MH, Stenning SP, Parkinson ME, et al: Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A Medical Research Council report. J Clin Oncol 14:1106-1113, 1996
23. Pont J, Albrecht W, Postner G, et al: Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial. J Clin Oncol 14:441-448, 1996
24. Böhlen D, Borner M, Sonntag RW, et al: Long-term results following adjuvant chemotherapy in patients with clinical stage I nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161:1148-1152, 1999